Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7EJ8S)

Drug Name
PF-06882961 Drug Info
Synonyms
2230198-02-2; UNII-DN9IUI24GP; DN9IUI24GP; 2230198-02-2 (free acid); (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid; 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid; Danuglipron; UK4; Danuglipron [USAN]; CHEMBL4518483; SCHEMBL20266351; BDBM349662; EX-A3607; WHO 11630; US10208019, Example 1A-09; US10208019, Example 4A-01; 2-[[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridyl]-1-piperidyl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid; AC-31472; PF6882961; Q63141738; 1H-Benzimidazole-6-carboxylic acid, 2-((4-(6-((4-cyano-2-fluorophenyl)methoxy)-2-pyridinyl)-1-piperidinyl)methyl)-1-((2S)-2-oxetanylmethyl)-; 2-{[4-(6-{[(4-cyano-2-fluorophenyl)(methyl-d2)]oxy}pyridin-2-yl)piperidin-1-yl]methyl}-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Phase 2 [1]
Cross-matching ID
PubChem CID
134611040
CAS Number
CAS 2230198-02-2
TTD Drug ID
DM7EJ8S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glucagon-like peptide 1 receptor (GLP1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Semaglutide DMAGFOD Type-2 diabetes 5A11 Approved [3]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [4]
Exenatide DMYHBKN Inflammation 1A00-CA43.1 Approved [5]
Dulaglutide DMYXBV3 Type-2 diabetes 5A11 Approved [6]
Lixisenatide DM0QJDC Type-2 diabetes 5A11 Approved [7]
Pramlintide DM0EZ9Q Type-1/2 diabetes 5A10-5A11 Approved [4]
Albiglutide DM1JEGF Type-2 diabetes 5A11 Approved [7]
Tirzepatide DMQNMAT Type 2 diabetes 5A11 Approved [8]
Efpeglenatide DMKA2PI Type-2 diabetes 5A11 Phase 3 [9]
GLP-1 DMR6YH3 Diabetic complication 5A2Y Phase 3 [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT03985293) A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
2 Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Mol Cell. 2020 Nov 5;80(3):485-500.e7.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
4 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
5 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
6 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
8 Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)